Document is current
Any future updates will be listed below
-
Authors
Inderberg, Else Marit https://orcid.org/0000-0002-6147-3536
Singh, Nand https://orcid.org/0009-0000-6683-7450
Miller, Robert https://orcid.org/0000-0003-2030-1778
Arbe-Barnes, Sarah https://orcid.org/0000-0003-0352-5307
Eriksen, Henrik K. https://orcid.org/0009-0008-3856-5775
lversen, Berit
Juul, Hedvig Vidarsdotter
Eriksen, Jon Amund https://orcid.org/0009-0007-9987-6764
Handeland, Karianne Risberg
-
Funding
Funding for this research was provided by:
Hubro Therapeutics AS
The Research Council of Norway (Project No.: 321590, Project No.: 321590, Project No.: 321590, Project No.: 321590, Project No.: 321590, Project No.: 321590)
- License Information
-
More Information
Article History
Received: 8 November 2024
Accepted: 3 February 2025
First Online: 25 February 2025
Declarations
:
: NS is an employee of Quotient Sciences which was contracted by Hubro Therapeutics AS to conduct the study. RMM, SA-B, HKE, BI, JAE and KRH were employed by study sponsor. EMI and HVJ are employees of Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital—Radiumhospitalet, Oslo, Norway. The authors have no relevant financial or non-financial interests to disclose. The authors have no conflicts of interest to declare that are relevant to the content of this article.
: This study was approved by the UK Medicines and Healthcare products Regulatory Agency and the protocol approved by the London – West London & Gene Therapy Advisory Committee Research Ethics Committee, the Norwegian National Research Ethics Committee and written informed consent was obtained from all subjects.
: The authors declare that they consent for publication.
